Literature DB >> 23886758

Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability.

Arlette Scheifes1, Daniël de Jong, Joost Jan Stolker, Henk L I Nijman, Toine C G Egberts, Eibert R Heerdink.   

Abstract

Psychotropic drugs are a cornerstone in the treatment of psychopathology and/or behavioral problems in children with intellectual disability (ID), despite concerns about efficacy and safety. Studies on the prevalence of psychotropic drug use have mainly been focused on adults with ID or children without ID. Therefore the aim of this cross sectional study was to assess the prevalence and characteristics of psychotropic drug use in children with mild ID who were institutionalized in specialized inpatient treatment facilities in The Netherlands. Demographic data, psychiatric diagnoses, the nature of the behavioral problems, level of intellectual functioning, and medication data were extracted from medical records using a standardized data collection form. Adjusted relative risks (ARR) for the association between patient characteristics and psychotropic drug use were estimated with Cox regression analysis. Of the 472 included children, 29.4% (n=139) used any psychotropic drug, of which 15.3% (n=72) used antipsychotics (mainly risperidone), and 14.8% (n=70) used psychostimulants (mainly methylphenidate). Age, sex, and behavioral problems were associated with psychotropic drug use. Boys had a 1.7 (95%CI 1.1-2.4) higher probability of using psychotropic drugs, compared to girls adjusted for age and behavioral problems. Having any behavioral problem was associated with psychotropic drug use with an ARR of 2.1 (95%CI 1.3-3.3), adjusted for sex and age. The high prevalence of psychotropic drug use in children with ID is worrisome because of the lack of evidence of effectiveness (especially for behavioral problems) at this young age, and the potential of adverse drug reactions.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Behavioral problems; Children and adolescents; Intellectual disability; Prevalence; Psychotropic drugs

Mesh:

Substances:

Year:  2013        PMID: 23886758     DOI: 10.1016/j.ridd.2013.06.009

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  1 in total

Review 1.  Polypharmacy in the treatment of subjects with intellectual disability.

Authors:  Frank Häβler; Johannes Thome; Olaf Reis
Journal:  J Neural Transm (Vienna)       Date:  2014-05-25       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.